Cargando…

High‐dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double‐blind, placebo‐controlled study with a long‐term open‐label extension study in Japan

BACKGROUND: A previous phase II dose‐ranging study of linaclotide in a Japanese chronic constipation (CC) population showed that 0.5 mg was the most effective dose. This study aimed to verify the hypothesis that 0.5 mg of linaclotide is effective and safe in Japanese CC patients. METHODS: This was a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fukudo, Shin, Miwa, Hiroto, Nakajima, Atsushi, Kinoshita, Yoshikazu, Kosako, Masanori, Hayashi, Kenta, Akiho, Hiraku, Kuroishi, Kentaro, Johnston, Jeffrey M, Currie, Mark, Ohkusa, Toshifumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379198/ https://www.ncbi.nlm.nih.gov/pubmed/30353619 http://dx.doi.org/10.1111/nmo.13487

Ejemplares similares

Impact of symptoms by gender and age in Japanese subjects with irritable bowel syndrome with constipation (IBS-C): a large population-based internet survey
por: Kosako, Masanori, et al.
Publicado: (2018)

Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey
por: Kosako, Masanori, et al.
Publicado: (2018)

Abdominal bloating is the most bothersome symptom in irritable bowel syndrome with constipation (IBS-C): a large population-based Internet survey in Japan
por: Kanazawa, Motoyori, et al.
Publicado: (2016)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial
por: Lacy, Brian E., et al.
Publicado: (2015)

Linaclotide: A New Option for the Treatment of Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation in Adults
por: Parker, Colleen H., et al.
Publicado: (2013)

Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation
por: Lee, Noel, et al.
Publicado: (2012)

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
por: Hamatani, Tatsuto, et al.
Publicado: (2020)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

Diagnosis and treatment of irritable bowel syndrome with predominant constipation in the primary-care setting: focus on linaclotide
por: Chandar, Apoorva Krishna
Publicado: (2017)

Optimizing the Use of Linaclotide in Patients with Constipation-Predominant Irritable Bowel Syndrome: An Expert Consensus Report
por: Rey, Enrique, et al.
Publicado: (2017)

Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States
por: Nag, Arpita, et al.
Publicado: (2020)

The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review
por: Baaleman, Desiree F., et al.
Publicado: (2021)

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
por: Chey, William D., et al.
Publicado: (2021)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Schoenfeld, Philip, et al.
Publicado: (2018)

The impact of abdominal pain on global measures in patients with chronic idiopathic constipation, before and after treatment with linaclotide: a pooled analysis of two randomised, double-blind, placebo-controlled, phase 3 trials
por: Chang, L, et al.
Publicado: (2014)

Improving the Gastrointestinal Stability of Linaclotide
por: Braga Emidio, Nayara, et al.
Publicado: (2021)

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
por: Rao, Satish, et al.
Publicado: (2012)

Comparison of the Efficacy and Safety of Different Doses of Linaclotide for Patients with Chronic Constipation: A Meta-Analysis and Bayesian Analysis
por: Yang, Jiao, et al.
Publicado: (2021)

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials
por: Brenner, Darren M., et al.
Publicado: (2023)

Gut Microbiota and Chronic Constipation: A Review and Update
por: Ohkusa, Toshifumi, et al.
Publicado: (2019)

Linaclotide induces secretion of cGMP from mouse colonic epithelium
por: Tchernychev, Boris, et al.
Publicado: (2013)

Exploratory, multicenter, open-label study to evaluate the effects of linaclotide in patients with chronic constipation with an insufficient response to magnesium oxide: A study protocol
por: Yoshihara, Tsutomu, et al.
Publicado: (2022)

Linaclotide for treating patients with irritable bowel syndrome with predominant constipation: a multicentre study of real-world data in China
por: Liu, Lan, et al.
Publicado: (2022)

Treatment Satisfaction With Current Medications for Chronic Constipation: An Internet Survey of Japanese Patients
por: Hayashi, Toshihiro, et al.
Publicado: (2022)

Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive and extra-digestive symptoms
por: Serrano-Falcón, Blanca, et al.
Publicado: (2019)

Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study
por: Brenner, Darren M., et al.
Publicado: (2020)

Lewy body constipation
por: Sakakibara, Ryuji, et al.
Publicado: (2019)

Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub‐cohort analysis of a phase III, randomized, double‐blind, placebo‐controlled trial
por: Peng, Li Hua, et al.
Publicado: (2022)

Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study
por: Pohl, Daniel, et al.
Publicado: (2019)

Safety and efficacy of long-term esomeprazole 20 mg in Japanese patients with a history of peptic ulcer receiving daily non-steroidal anti-inflammatory drugs
por: Sugano, Kentaro, et al.
Publicado: (2013)

Responders vs clinical response: a critical analysis of data from linaclotide phase 3 clinical trials in IBS-C
por: Lacy, B E, et al.
Publicado: (2014)

Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea
por: Ida, Motoko, et al.
Publicado: (2017)

Linaclotide for the treatment of refractory lower bowel manifestations of systemic sclerosis
por: Dein, Eric J., et al.
Publicado: (2021)

A New Regioselective Synthesis of the Cysteine-Rich Peptide Linaclotide
por: Qiu, Zhonghao, et al.
Publicado: (2023)

Polyethylene glycol 3350 plus electrolytes for chronic constipation: a 2-week, randomized, double-blind, placebo-controlled study with a 52-week open-label extension
por: Nakajima, Atsushi, et al.
Publicado: (2019)

Effect of Mizagliflozin on Postprandial Plasma Glucose in Patients With Functional Constipation
por: Fukudo, Shin, et al.
Publicado: (2019)

Clarification of Linaclotide Pharmacology Presented in a Recent Clinical Study of Plecanatide
por: Busby, Robert W., et al.
Publicado: (2014)

Engineering of an Anti-Inflammatory Peptide Based on the Disulfide-Rich Linaclotide Scaffold
por: Cobos, Claudia, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5o92f5kb8evlesifj022t6msq7